A detailed history of Charles Schwab Investment Management Inc transactions in Liquidia Corp stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 133,044 shares of LQDA stock, worth $1.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
133,044
Previous 131,764 0.97%
Holding current value
$1.57 Million
Previous $1.59 Million 23.79%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$11.35 - $16.73 $14,528 - $21,414
1,280 Added 0.97%
133,044 $1.96 Million
Q4 2023

Feb 06, 2024

SELL
$5.77 - $12.19 $7,916 - $16,724
-1,372 Reduced 1.03%
131,764 $1.59 Million
Q3 2023

Nov 08, 2023

BUY
$6.27 - $8.15 $24,089 - $31,312
3,842 Added 2.97%
133,136 $844,000
Q2 2023

Aug 09, 2023

SELL
$6.63 - $9.9 $7,597 - $11,345
-1,146 Reduced 0.88%
129,294 $1.01 Million
Q1 2023

May 11, 2023

BUY
$5.72 - $7.91 $18,681 - $25,834
3,266 Added 2.57%
130,440 $901,000
Q4 2022

Feb 13, 2023

BUY
$4.68 - $6.54 $2,695 - $3,767
576 Added 0.45%
127,174 $810,000
Q3 2022

Nov 14, 2022

BUY
$3.73 - $8.39 $3,550 - $7,987
952 Added 0.76%
126,598 $689,000
Q2 2022

Aug 15, 2022

BUY
$3.37 - $7.55 $353,354 - $791,640
104,853 Added 504.27%
125,646 $548,000
Q2 2021

Aug 16, 2021

SELL
$2.51 - $3.11 $95,711 - $118,590
-38,132 Reduced 64.71%
20,793 $60,000
Q3 2020

Nov 13, 2020

BUY
$4.34 - $8.28 $53,390 - $101,860
12,302 Added 26.39%
58,925 $290,000
Q2 2020

Aug 14, 2020

BUY
$4.86 - $11.44 $77,473 - $182,365
15,941 Added 51.96%
46,623 $393,000
Q2 2019

Aug 09, 2019

BUY
$7.92 - $11.39 $106,935 - $153,787
13,502 Added 78.59%
30,682 $246,000
Q1 2019

May 14, 2019

BUY
$10.82 - $21.79 $85,694 - $172,576
7,920 Added 85.53%
17,180 $196,000
Q3 2018

Nov 13, 2018

BUY
$10.96 - $28.9 $101,489 - $267,614
9,260 New
9,260 $255,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $761M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.